产品
编 号：F200292
分子式：C17H12F3NO4S
分子量：383.34
分子式：C17H12F3NO4S
分子量：383.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
2mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1672665-49-4
产品详情
生物活性：
PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM.
体内研究：
PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression. PT-2385 (PT2385) inhibits expression of HIF-2α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31).Animal Model:SCID/beige mice with the 786-O and A498 RCC cell lines
Dosage:30 or 100 mg/kg
Administration:Oral gavage; twice daily
Result:Resulted in a rapid, dose-dependent tumor regression.
体外研究：
PT-2385 (PT2385) is a selective antagonist of HIF-2 over HIF-1. PT-2385 is inactive for HIF-1α.
PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM.
体内研究：
PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression. PT-2385 (PT2385) inhibits expression of HIF-2α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31).Animal Model:SCID/beige mice with the 786-O and A498 RCC cell lines
Dosage:30 or 100 mg/kg
Administration:Oral gavage; twice daily
Result:Resulted in a rapid, dose-dependent tumor regression.
体外研究：
PT-2385 (PT2385) is a selective antagonist of HIF-2 over HIF-1. PT-2385 is inactive for HIF-1α.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备